bims-ecasc1 Biomed News
on Enoyl Coenzyme A hydratase, short chain, 1
Issue of 2025–03–16
three papers selected by
Bill Suzor, Cure Mito Foundation



  1. Cell Rep. 2025 Mar 06. pii: S2211-1247(25)00150-0. [Epub ahead of print]44(3): 115379
      The absence of HIBCH or ECHS1, two Leigh syndrome genes, in cultured cells results in abnormal mitochondrial morphology and respiratory defects. Fly eyes lacking either protein exhibit age-dependent degeneration. Elevated lysine methacrylation (Kmea) is observed in both HIBCH- and ECHS1-deficient cells and fly tissues. Quantitative mass spectrometry reveals that many proteins are ectopically modified by Kmea in these cells. Mimicking Kmea in proteins like CH60, FKBP4, BIP, LDHB, or DHRS2 replicates the mitochondrial morphology changes seen in HIBCH- or ECHS1-deficient cells. Reducing Kmea modification partially rescues mitochondrial morphology changes in cells and eye degeneration in flies. Fibroblasts from patients with HIBCH or ECHS1 mutations show similar mitochondrial changes and elevated Kmea, which are significantly reversed by administering N-acetyl-L-cysteine to reduce Kmea levels. We propose that ectopic Kmea modification mediates the defects caused by HIBCH- or ECHS1-deficiency. Reducing Kmea modification provides a new approach for treating HIBCH- or ECHS1-related Leigh syndrome.
    Keywords:  CP: Molecular biology; CP: Neuroscience; Drosophila; ECHS1; HIBCH; Leigh syndrome; lysine methacrylation; mitochondria; neurodegeneration
    DOI:  https://doi.org/10.1016/j.celrep.2025.115379
  2. PLoS One. 2025 ;20(3): e0319049
      Focal segmental glomerulosclerosis (FSGS) is a common cause of nephrotic syndrome and often leads to end-stage renal disease. However, the underlying pathophysiological mechanisms that contribute to disease progression require further investigation to establish appropriate therapeutic targets and biomarkers. This study aimed to clarify the molecular mechanisms underlying FSGS by focusing on differentially expressed genes (DEGs) and lipid metabolism-related genes (LMRGs). We utilized the GSE69814, GSE129973, and GSE121233 datasets, which comprise glomerular transcriptomes from patients with FSGS, minimal change disease (MCD), and unaffected kidney tissues. We identified 2,459 DEGs from the GSE69814 dataset and 982 DEGs from the GSE129973 dataset. These DEGs intersected 1,450 LMRGs, resulting in 56 differentially expressed LMRGs (DELMRGs). Enrichment analysis revealed that these DELMRGs were primarily involved in fatty acid metabolic processes; localized in microbodies, peroxisomes, and mitochondrial matrices; and exhibited oxidoreductase activity. Protein-protein interaction networks were constructed using Cytoscape, and five hub DELMRGs (enoyl-CoA hydratase, short chain 1 [ECHS1], EHHADH, IDH1, SUCLG1, and ALDH3A2) were identified using multiple algorithms. We assessed the diagnostic performance using receiver operating characteristic curves and expression levels from the GSE121233 dataset, and found that ECHS1 and ALDH3A2 showed strong diagnostic potential. Immunohistochemical verification of clinical specimens from children confirmed significant expression of ECHS1 in FSGS compared with that in normal and MCD tissues. This study highlights ECHS1 as a potential biomarker for pediatric FSGS, suggesting a potential role in early diagnosis or personalized treatment, offering insights into its pathogenesis and paving the way for targeted therapeutic strategies.
    DOI:  https://doi.org/10.1371/journal.pone.0319049
  3. J Cereb Blood Flow Metab. 2025 Mar 13. 271678X251325805
      Demyelination is a common feature of neuroinflammatory and degenerative diseases of the central nervous system (CNS), such as multiple sclerosis (MS). It is often linked to disruptions in intercellular communication, bioenergetics and metabolic balance accompanied by mitochondrial dysfunction in cells such as oligodendrocytes, neurons, astrocytes, and microglia. Although current MS treatments focus on immunomodulation, they fail to stop or reverse demyelination's progression. Recent advancements highlight intercellular mitochondrial exchange as a promising therapeutic target, with potential to restore metabolic homeostasis, enhance immunomodulation, and promote myelin repair. With this review we will provide insights into the CNS intercellular metabolic decoupling, focusing on the role of mitochondrial dysfunction in neuroinflammatory demyelinating conditions. We will then discuss emerging cell-free biotherapies exploring the therapeutic potential of transferring mitochondria via biogenic carriers like extracellular vesicles (EVs) or synthetic liposomes, aimed at enhancing mitochondrial function and metabolic support for CNS and myelin repair. Lastly, we address the key challenges for the clinical application of these strategies and discuss future directions to optimize mitochondrial biotherapies. The advancements in this field hold promise for restoring metabolic homeostasis, and enhancing myelin repair, potentially transforming the therapeutic landscape for neuroinflammatory and demyelinating diseases.
    Keywords:  Extracellular vesicles (EVs); cell-free biotherapy; demyelination; mitochondria transfer; neuroinflammation
    DOI:  https://doi.org/10.1177/0271678X251325805